Dr Erwin Blomsma, Co-founder & CEO, ViroVet

Dr Erwin Blomsma, Co-founder & CEO, ViroVet

• 1.
  Animal Health Asia20/10/2016 [email protected] 1 Providing innovative virus control solutions to secure and improve the health and value of livestock > 1.5 billion > 2 billion > 1 billion> 23 billion
• 2.
  Animal Health Asia20/10/2016 [email protected] 2 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 0 20 40 60 80 100 120 1960 201019851975 2000 billion people million tonnes sheep & goat poultry eggs cattle pigs middle class Global meat production
• 3.
  Animal Health Asia20/10/2016 [email protected] 3 Our Business Providing innovative virus control solutions to secure and improve the health and value of livestock and reduce the use of antibiotics • Fast acting antiviral drugs – Immediate effect (no immunity gap) – Broad activity across strains – Filtering out infected animals (immune response) • Better vaccines – Increased efficiency and DIVA – No need for cold chain – Quickly adaptable and low cost ACT NOW ACT LONG Antiviral Technology Rega Institute for Medical Research Atripla HIV / Hepsera Hepatitis Active Pharmaceutical Ingredients / NCE
• 4.
  Animal Health Asia20/10/2016 [email protected] 4 Vaccine Technology Platform Rega Institute for Medical Research Large Pharma Companies Yellow fever, Zika, etc Veterinary Applications of Vaccine Technology Human Field Our foundations 44mn$ Acquisition January 6, 2014 Rega Institute for Medical Research €8,5mn Series A on October 17, 2008 • New Belgian SME • Probably the first • Product pipeline • 5 for pets • 2 for livestock Veterinary rights on Human Antiviral Drugs Atripla HIV / Hepsera Hepatitis • Nasdaq PETX • Development company of Pet Products • FDA priority • EU preparation Spin-off July 30, 2015 Vaccine technology New antivirals Vaccine Technology
• 5.
  Animal Health Asia20/10/2016 [email protected] 5 Feeding the world 70% 80% Increase of calories needed to feed 9.5 billionpeople Rise in demand of animal based food 1.8bn >5bn 2010 2050 Limited pasture requires smart farming Output Productivity Environmental changes Increase of vector-borne diseases Globalisation (incl tourism) Increased spread of viral diseases Antibiotic resistance leading to zoonoses 80% of all antibiotics are used in livestock Provide fast acting antivirals Broad activity, ‘DIVA’, treat & protect Launch better vaccines Stable, DIVA, low cost, prevent disease Bovine and Porcine Respiratory Disease Complex Novel drugs and vaccines for BVD and PRRS, reduce antibiotics Epizootics and emerging zoonotic threats Antivirals to control ASF, novel flu and RVF vaccines with innovation Providing innovative virus control solutions to secure and improve the health and value of livestock 2016